Table 3.
Associations between baseline Mets-IR with follow-up incident CVD/Stroke/Heart- disease.
| Model 1 | P | Model 2 | P | Model 3 | P | |
|---|---|---|---|---|---|---|
| CVD | ||||||
| Mets-IR Per IQR | 1.26 (1.11,1.43) | <0.001 | 1.35 (1.19,1.53) | <0.001 | 1.38 (1.21,1.56) | <0.001 |
| Q1 | ref | ref | ref | |||
| Q2 | 1.09 (0.82,1.44) | 0.567 | 1.16 (0.87,1.54) | 0.311 | 1.17 (0.88,1.56) | 0.279 |
| Q3 | 1.24 (0.94,1.63) | 0.126 | 1.36 (1.03,1.80) | 0.030 | 1.39 (1.05,1.84) | 0.021 |
| Q4 | 1.53 (1.18,2.00) | 0.002 | 1.75 (1.33,2.30) | <0.001 | 1.81 (1.37,2.38) | <0.001 |
| P for trend | <0.001 | <0.001 | <0.001 | |||
| Heart- disease | ||||||
| Mets-IR Per IQR | 1.22 (1.05,1.41) | 0.011 | 1.26 (1.08,1.47) | <0.001 | 1.29 (1.10,1.50) | <0.001 |
| Q1 | ref | ref | ref | |||
| Q2 | 0.96 (0.68,1.34) | 0.796 | 0.99 (0.70,1.39) | 0.950 | 1.00 (0.71,1.41) | 0.983 |
| Q3 | 1.09 (0.78,1.51) | 0.614 | 1.13 (0.81,1.59) | 0.463 | 1.17 (0.83,1.63) | 0.373 |
| Q4 | 1.41 (1.03,1.93) | 0.033 | 1.49 (1.08,2.06) | 0.015 | 1.55 (1.12,2.16) | 0.008 |
| P for trend | 0.020 | 0.009 | 0.005 | |||
| Stroke | ||||||
| Mets-IR Per IQR | 1.34 (1.11,1.61) | 0.002 | 1.50 (1.25,1.82) | <0.001 | 1.51 (1.25,1.83) | <0.001 |
| Q1 | ref | ref | ref | |||
| Q2 | 1.52 (0.98,2.39) | 0.062 | 1.70 (1.09,2.67) | 0.019 | 1.71 (1.10,2.70) | 0.018 |
| Q3 | 1.62 (1.05,2.53) | 0.031 | 1.93 (1.24,3.03) | 0.004 | 1.95 (1.26,3.07) | 0.003 |
| Q4 | 1.94 (1.27,2.99) | 0.002 | 2.46 (1.60,3.83) | <0.001 | 2.49 (1.61,3.90) | <0.001 |
| P for trend | 0.003 | <0.001 | <0.001 | |||
Model 1 was crude model. Model 2 was adjusted for age, gender, education level, location, and marital status. Model 3 was furthrt for smoking status, drinking status and sleep time.
CVD, Cardiovascular disease; METS-IR, Metabolic Score for Insulin Resistance; IQR, interquartile range.